News

Don’t hesitate one more minute!

Register here for the Myasthenia Alliance Australia (MAA) Integrating Physiotherapy into Your Care Team with Physiotherapist Rodney Wenceslao.

Register here for the Myasthenia Alliance Australia (MAA) Integrating Physiotherapy into Your Care Team with Physiotherapist Rodney Wenceslao.

Generalised Myasthenia Gravis (gMG) patients can now have access to a new targeted therapy Ultomiris, via the Pharmaceutical Benefits Scheme (PBS), broadening our treatment options.*

The MAA shared the important moment when Minister Butler announced that this new treatment has been listed, at the annual Rare Disease Day parliamentary event.

Good news. The MAA are pleased to share content from the Optimal CRE Research Project November 2025 webinar and also an opportunity to be involved in future research offered through this project.

Did you know 300 million people worldwide are living with a rare disease?

The MAA is pleased to share with you that a clinical trial is now open for Australian participation. It will potentially offer an additional treatment pathway for myasthenia gravis patients.

Recently we announced an important research collaboration between the Myasthenia Gravis Association of Queensland and Queensland University of Technology.

Once again, it is time to celebrate with Rare Voices Australia (RVA) as they host a parliamentary event in honour of rare diseases day 2026.

It is a privilege to have myasthenia gravis represented at this significant event and we express sincere appreciation to RVA for our inclusion. This meeting allows the MAA to speak with Federal politicians about the challenges of rare disease care and to bring awareness of our unique condition and many unmet needs.

Thank You to the Myasthenia Gravis Community

The VALUE-MG study has officially reached its recruitment target, with 216 people living with myasthenia gravis participating across five hospital sites in Australia.

This important research is helping build a clearer picture of how myasthenia gravis affects people’s health, daily activities and work over time, and how these experiences link with real-world treatment and healthcare use.